ArticleBMC microbiology2026
Multi-omics integration to elucidate the antibacterial mechanism of Streptomyces sp. strain PBSH9.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Potato common scab, incited by pathogenic Streptomyces species, poses a significant threat to agriculture. The biocontrol agent Streptomyces sp. strain PBSH9 has shown remarkable field efficacy, yet its underlying antibacterial mechanisms remain unclear. To bridge this knowledge gap, we employed an integrated transcriptomic, proteomic, and metabolomic approach to compare PBSH9 under high (8-day) and low (2-day) antibacterial activity conditions. Transcriptomics identified 2,653 differentially expressed genes (DEGs), primarily enriched in oxidative phosphorylation and β-lactam resistance pathways. Proteomics quantified 32 differentially abundant proteins (DAPs), which were also predominantly involved in energy metabolism. Critically, metabolomic profiling of 1,299 differential metabolites (DAMs) revealed the core of the antibacterial activity: a massive > 28-fold accumulation of the antibiotics L-anticapsin and bacilysin, coupled with a significant 1.08- to 2.85-fold increase in several aminoglycoside antibiotics, including neomycin B and kanamycin. This enhanced antibiotic production was supported by the systematic upregulation of energy metabolism pathways, such as oxidative phosphorylation and the TCA cycle. Multi-dimensional correlation networks linked antibiotic accumulation to DEGs (st, phzF) and DAPs. Our findings demonstrate that the potent biocontrol activity of PBSH9 stems from a metabolic reprogramming that fuels the synergistic accumulation of a diverse antibiotic arsenal. This study provides a comprehensive molecular blueprint for optimizing and engineering this promising biocontrol strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.